Trial Profile
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Dec 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Cytarabine (Primary) ; Ruxolitinib (Primary) ; Uzansertib (Primary)
- Indications Acute myeloid leukaemia; Myelofibrosis; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Incyte Corporation
- 09 Nov 2021 Status changed from completed to discontinued.
- 06 Apr 2021 Status changed from active, no longer recruiting to completed.
- 17 Jul 2020 Status changed from recruiting to active, no longer recruiting.